SLFN11 and small cell lung carcinoma: These findings highlight the potential of SLFN11‐guided treatment strategies to optimize therapeutic outcomes in SCLC, though further studies are needed to refine biomarker thresholds and there is a potential to add SCLC subtypes or Delta‐like ligand 3 as well to improve this potential marker to be synergistic to other biomarkers.